Spermosens

Spermosens completes development of JUNO-Checked Generation 3 and initiates clinical validation study

Spermosens AB (“Spermosens” or the “Company”) announces that development of the JUNO-Checked Generation 3 system is now complete.  This innovative sensor system meets the performance standards necessary for a commercially viable product. The Company is preparing to initiate patient recruitment for a clinical validation study at the Reproductive Medicine Center (RMC) in Malmö. This represents a major milestone in the strategic plan to bring improved fertility diagnostics to the market through commercial partnerships.

Spermosens AB (publ) Issues Final Reminder for Tomorrow’s Live Q&A Webcast

Spermosens AB (publ) (“Spermosens”) provides a final reminder for its live digital Q&A webcast scheduled for tomorrow, Thursday, 26 March 2026, at 12:00 CET.

Spermosens AB (publ) to Host Live Q&A Webcast Following Recent Progress

Spermosens AB (publ) (“Spermosens” or the “Company”) today announces that it will host a live Q&A webcast on Thursday, 26 March 2026, at 12:00 CET. CEO Tore Duvold will address questions regarding the Company’s recent announcements and ongoing technical, clinical and commercial developments.

Spermosens AB (publ)YEAR-END REPORT JANUARY – DECEMBER 2025 - CORRECTED

Spermosens AB (publ)YEAR-END REPORT JANUARY – DECEMBER 2025

Spermosens and RSI sign Memorandum of Understanding to advance male fertility diagnostics in the US

Spermosens AB has entered into a Memorandum of Understanding (MoU) with RSI Technology Group (RSI), a US-based medical device company developing innovative solutions for sperm collection and preparation. The MoU reflects the parties’ intention to explore a potential collaboration aimed at evaluating a combined approach for introducing Spermosens’ diagnostic method, JUNO‑Checked, into the United States fertility market.

Spermosens and Sapyen sign Memorandum of Understanding to advance male fertility diagnostics

Spermosens AB has entered into a Memorandum of Understanding (MoU) with Sapyen, a global male fertility diagnostics company with operations across the US, Europe, UK and Australia. The MoU reflects the parties’ intention to evaluate a potential collaboration with the aim of establishing a partner-led commercialization model for Spermosens’ diagnostic method, JUNO-Checked.

Spermosens shares progress and plans for partner-driven commercialization

Spermosens AB (“Spermosens” or the “Company”) presents an update on recent progress and the next steps in its partner-driven commercialization strategy for JUNO-Checked. The Company completed a successful clinical study in June 2025, confirming the diagnostic value of JUNO-Checked and continues to build a strong foundation for a partner-led market introduction. Development of Generation 3, the intended commercial version, is progressing and dialogues with potential partners in Europe, the United States, Japan and Australia are advancing. Central to the Company’s go-to-market strategy is the establishment of licensing and partnership structures that support regulatory activities, market adaptation and commercial rollout.

Spermosens announces outcome of exercise of warrants series TO 4